Nuvation Bio Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Nuvation Bio Inc. (NUVB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of -$17.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Nuvation Bio Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was -$17.14M, a 242.42% decline year-over-year.
- Nuvation Bio Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $9.03M, a 15.01% increase year-over-year.
- Nuvation Bio Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $8.02M, a 7.29% increase year-over-year.
- Nuvation Bio Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $12.03M, a 25.73% increase year-over-year.
- Nuvation Bio Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $35.89M, a 11.21% increase from fiscal 2024.
- Nuvation Bio Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $32.27M, a 65.40% increase from fiscal 2023.
- Nuvation Bio Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $19.51M, a 19.77% increase from fiscal 2022.
- Nuvation Bio Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $16.29M, a 75.79% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$17.14M 10-Q · filed 2026-08-06 | -$8.10M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $9.03M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $35.89M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $8.02M 10-Q · filed 2025-11-03 | $20.05M derived: sum of 2 quarters · filed 2026-08-06 | $27.91M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $12.03M 10-Q · filed 2026-08-06 | $19.89M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $7.85M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $32.27M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $7.48M 10-Q · filed 2025-11-03 | $17.05M derived: sum of 2 quarters · filed 2025-11-03 | $22.09M derived: sum of 3 quarters · filed 2025-11-03 | |
| 2024-06-30 | $9.57M 10-Q · filed 2025-11-03 | $14.61M derived: sum of 2 quarters · filed 2025-11-03 | ||
| 2024-03-31 | $5.04M 10-Q · filed 2025-11-03 | |||
| 2023-12-31 | $19.51M 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $5.43M 10-Q · filed 2024-11-06 | $10.95M derived: sum of 2 quarters · filed 2024-11-06 | $15.79M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $5.52M 10-Q · filed 2024-11-06 | $10.36M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $4.84M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $16.29M 10-K · filed 2024-02-29 | |||
| 2022-09-30 | $2.94M 10-Q · filed 2023-11-02 | $7.73M derived: sum of 2 quarters · filed 2023-11-02 | $11.30M derived: sum of 3 quarters · filed 2023-11-02 | |
| 2022-06-30 | $4.79M 10-Q · filed 2023-11-02 | $8.36M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | $3.58M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $9.27M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $2.75M 10-Q · filed 2022-11-03 | $4.90M derived: sum of 2 quarters · filed 2022-11-03 | $6.47M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $2.15M 10-Q · filed 2022-11-03 | $3.72M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $1.57M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $2.20M 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $348.00K 10-Q · filed 2021-11-10 | $737.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.08M derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $389.00K 10-Q · filed 2021-11-10 | $729.00K derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $340.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |